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Aberrant promoter hypermethylation is frequently observed in
cancer. The potential for this mechanism to contribute to tumor de-
velopment depends on whether the genes affected are repressed
because of their methylation. Many aberrantly methylated genes
play important roles in development and are bivalently marked in
ES cells, suggesting that their aberrant methylation may reﬂect de-
velopmental processes.We investigated this possibility by analyzing
promoter methylation in 19 breast cancer cell lines and 47 primary
breast tumors. In cell lines, we deﬁned 120 genes that were signif-
icantly repressed in association with methylation (SRAM). These
genes allowed the unsupervised segregation of cell lines into epi-
thelial (EPCAM+ve) and mesenchymal (EPCAM−ve) lineages. How-
ever, themethylatedgeneswere already repressed innormal cells of
the same lineage, and>90% could not be derepressed by treatment
with 5-aza-2′-deoxycytidine. The tumor suppressor genes APC and
CDH1 were among those methylated in a lineage-speciﬁc fashion.
As predicted by the epithelial nature of most breast tumors, SRAM
genes that were methylated in epithelial cell lines were frequently
aberrantly methylated in primary tumors, as were genes speciﬁcally
repressed in normal epithelial cells. An SRAM gene expression sig-
nature also correctly identiﬁed the rare claudin-low and metaplastic
tumors as having mesenchymal characteristics. Our ﬁndings impli-
cate aberrant DNA methylation as a marker of cell lineage rather
than tumor progression and suggest that, in most cases, it does
not cause the repression with which it is associated.
Aberrant CpG island methylation occurs in cancer and is im-plicated in tumor progression (1), particularly when methyl-
ation of a tumor suppressor gene appears to phenocopy the
equivalent genetic mutation. Examples include MLH1 methyla-
tion in sporadic microsatellite unstable colon cancer (2) and Rb in
retinoblastoma (3).
Several tumor suppressor genes and putative tumor suppressor
genes have been reported to bemethylated in breast cancer (4), but
in most cases, evidence for a functional role in tumorigenesis is
lacking. BRCA1, which is mutated in familial breast cancer, is
reported to bemethylated in∼10%of sporadic tumors. In BRCA1-
associated familial tumors, thewild-typeBRCA1allele is frequently
lost. One report suggested that the loss of function could occur
through methylation of the remaining wild-type allele (5), but this
ﬁnding has not been supported by subsequent, larger studies (6, 7).
Breast development begins in embryonic life when epidermal
cells of ectodermal origin project into themesenchyme underlying
the mammary ridge and form lactiferous ducts. Mammary stem
cells give rise to both the inner luminal-epithelial and the outer
“basal” myoepithelial cells of the lobulo-ductal system (8). Pri-
mary breast tumors can been subdivided into many different types
by histology and by molecular proﬁling, but most tumors are
thought to be epithelial in origin, deriving either from luminal-
epithelial cells or from their progenitors (9).
It is known that many genes de novo methylated in cancer have
“bivalent” histone marks (combined histone H3 lysine-27 and
lysine-4 trimethylation) in embryonic stem (ES) cells (10). Because
bivalently marked genes frequently have a role in development, we
asked whether cancer-associated aberrant methylation might re-
ﬂect the particular cell lineage from which a breast tumor was
derived (its ontogeny). We show that aberrant DNA methylation
occurs in genes down-regulated through normal lineage commit-
ment and that the genes affected can be used to distinguish breast
tumors of epithelial and mesenchymal lineage. We propose that
most aberrant methylation reﬂects lineage commitment rather
than tumor progression.
Results
DNA Methylation Occurs Variably Across Breast Cancer Cell Lines and
Is Associated with Gene Repression. We correlated promoter
methylation with gene expression by analyzing 19 breast cancer
cell lines on Inﬁnium arrays and combining these results with
published transcriptome data (11). Inﬁnium arrays assay the
proportion of 5-methylcytosine to total cytosine at 27,578 dif-
ferent CpG dinucleotides in >14,000 genes after bisulﬁte con-
version (12). We validated the capacity of the Inﬁnium arrays to
detect changes in DNA methylation by using DNA from wild-
type and DNA methyltransferase deﬁcient HCT116 colon cancer
cell lines (Fig. S1A). The methylation levels reported by the
arrays also corresponded well to those assayed by bisulﬁte se-
quencing, both for the individual CpGs interrogated and for
neighboring CpGs (Fig. S1 B and C). We restricted our analysis
to probes within 200 bp of transcription start sites because we
were interested in the effects of methylation on expression. As
expected, genes associated with methylated promoters were less
expressed than genes with unmethylated promoters (Fig. S1D).
To understand the factors that might be inﬂuencing methyla-
tion in the cell lines, we categorized the CpG probes into three
groups depending on their consistency of methylation across the
cell lines (Fig. 1A and Materials and Methods) and determined
the proportion of CpG island genes with each group. Most
consistently unmethylated (CU) probes (3,901 genes) were lo-
cated within CpG islands, whereas consistently methylated (CM)
probes (259 genes) were mostly located at non-CpG island
promoters (Fig. S1E). Variably methylated (VM) probes (1,023
genes) were signiﬁcantly more likely to be in CpG islands than
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CM probes (51% vs. 24%). VM genes were frequently not
expressed even when unmethylated, with 45% being unexpressed
in all 19 cell lines (Fig. S1F). However, a signiﬁcant proportion
(12%) of the VM genes did show the expected inverse relation-
ship between DNA methylation and expression (Fig. 1B).
Methylated and Variably Methylated Genes Have Tissue-Speciﬁc
Expression Patterns. We functionally characterized the gene groups
using Gene Ontology (GO) terms (Fig. S1G). CU genes were asso-
ciatedwithmetabolic or housekeeping processes, whereasCMgenes
were associated withmore specialized, lineage-restricted terms, such
as meiosis, and mast cell activation. In contrast, VM genes were
signiﬁcantly associated with general developmental processes.
Given that genes with different methylation patterns were
associated with different functions, we examined whether they
also had different patterns of expression in normal tissues by
scoring them according to their degree of tissue speciﬁcity (SI
Materials and Methods). CU genes were signiﬁcantly enriched in
genes showing a housekeeping expression pattern (Fig. 1C). In
contrast, VM genes were signiﬁcantly enriched for tissue-speciﬁc
expression. CM genes displayed a similar pattern to VM genes
but did not quite reach signiﬁcance (P = 0.065). The tissue
speciﬁcity of VM genes was also apparent when VM genes with
CpG island and non-CpG island promoters were analyzed sep-
arately (Fig. S1H).
CpGs That Are Variably Methylated in Cell Lines Are Frequently
Unmethylated in Normal Breast Tissue and Normal Mammary
Epithelial Cells. We next asked whether it was the CM or VM
probes that could be regarded as aberrantly methylated in cancer
because they were unmethylated in normal human mammary
epithelial cells (HMEC) and normal breast tissue. CU probes
were nearly always unmethylated in the normal DNA samples. A
high proportion of VM probes (58–66%) were also unmethy-
lated in these normal samples, and this was a signiﬁcantly greater
proportion than was found for the CM probes (5–7%, P < 2.2 ×
10−16, Fisher’s exact tests; Fig. 2A). As there were also ∼4 times
more VM genes (n = 1,023) than CM genes (n = 259), aberrant
methylation was signiﬁcantly more likely to occur at VM genes.
VM probes were also more likely to be unmethylated than CM
probes in a panel of nine normal tissues and in human ES (hES)
cells (Fig. S2 A and B).
VM Genes Are Enriched for “Bivalent” Histone Marks in hES Cells.
Cancer-associated aberrant methylation frequently occurs at
genes with bivalent histone marks in hES cells (histone H3K4me3
and H3K27me3; ref. 10). We noticed a striking similarity between
functional terms associated with VM genes and those previously
associated with bivalently marked genes in hES cells (Fig. S2C;
ref. 13). We used data from this study to determine the histone
marks associated with CU, CM, and VM genes in hES cells. A
signiﬁcant proportion of CU genes were marked by H3K4me3
alone (P < 2 × 10−16, Fisher’s exact test), whereas most CM and
VM genes lacked H3K4me3 and H3K27me3 (Fig. 2B). However,
the VM group was signiﬁcantly enriched for bivalent marks
(16.9% of the total; P = 7 × 10−22, Fisher’s exact test) compared
with the control. This enrichment was not seen in the CM group.
Genes That Are Signiﬁcantly Repressed in AssociationwithMethylation
(SRAM) Segregate Breast Cancer Cell Lines into Epithelial and Mesen-
chymal Lineages. As VM genes were lineage-speciﬁc, we asked
whether they could be used to categorize the cell lines according
to lineage. The expression levels of the 1,000 most variably
expressed genes segregated the 19 breast cancer cell lines into the
previously described luminal, basal A, and basal B subtypes (Fig.
3A; ref. 11). However, hierarchical clustering using methylation
levels of the 1,023 VM genes derived different groupings (Fig.
3B): Two of the basal A cell lines (MDAMB468 and HCC1954)
now clustered with the luminal cell lines. As not all VM genes
showed a good correlation with repression (Fig. 1B), we repeated
the analysis using the expression levels of those VM genes that
were signiﬁcantly repressed in association with methylation
(SRAM; 120 genes; Fig. 3C and Dataset S1). In this analysis, all
of the basal A cell lines clustered with the luminal cell lines.
Similar results were observed when we used only those SRAM
genes with CpG island promoters (67 genes; Fig. 3A).
The classiﬁcation based on SRAM genes correlated well with
cell morphology; the luminal group cells generally grew as tight
clusters typical of epithelial cells, whereas the other group
showed less cell–cell contact and were spindle-shaped (Fig. S3B).
The epithelium-like cells were all exclusively positive for the
epithelial marker EPCAM (also known as TACSTD1 and rec-
ognized by the BerEP4 antibody; Fig. 3D) and, with the excep-
tion of HCC1569, all expressed cytokeratin 19 and other markers
expressed by normal epithelial cells (Fig. 3E; ref.14). In contrast,
the other group was negative for EPCAM expression and, with
the exception of MCF10A cells, did not consistently express
keratins. However, they did express genes associated with mes-
enchyme (Fig. 3E; ref. 15). These data indicated that EPCAM−
ve cells were likely to be of mesenchymal lineage. Thus, the
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differential expression of SRAM genes classiﬁed breast cancer
cell lines into those of epithelial and mesenchymal lineage.
SRAM Genes Undergo Lineage-Speciﬁc Repression. Heat maps of
SRAM gene expression and methylation illustrate the striking
patterns that differentiate epithelial and mesenchymal cell lines
(Fig. 4A; larger heat maps are presented in Fig. S4A). The SRAM
gene list containsAPC,GSTP1, and PYCARD (16, 17), which have
been reported to be methylated in breast cancer, and CLDN7,
a tight junction protein expressed in epithelial cells that is methyl-
ated in some breast cancer cell lines (18). It also contains genes
that have been shown to be differentially expressed in different
subcompartments of the normal breast (for example, SPARC and
MB; refs. 19 and 20). Indeed, 71 SRAM genes are included in
published signatures of different cell populations puriﬁed from
normal breast tissue (21), a highly signiﬁcant enrichment (P=7.1×
10−16, Fisher’s exact test).
To determine whether the SRAM genes were coordinately re-
pressed in association with lineage in the normal breast, we in-
terrogated the same dataset of normal cell populations (21). SRAM
genes preferentially methylated in EPCAM+ve breast cancer cell
lines had signiﬁcantly lower levels of expression in cellular fractions
corresponding to differentiated luminal and luminal progenitor
cells (both EPCAM+ve, Wilcoxon test; Fig. 4B). In contrast, genes
methylated in EPCAM−ve breast cancer cell lines had signiﬁcantly
lower levels of expression in the basal/myoepithelial cell fraction and
even lower levels of expression in the mesenchymal stromal fraction
(both EPCAM−ve, Wilcoxon test; Fig. 4B). A similar pattern was
observed when we considered SRAM genes with CpG island and
non-CpG island promoters separately (Fig. S4B). Thus, genes prone
tomethylation in cell lines of different lineages are generally already
repressed in normal cells of the corresponding lineage.
Majority of Genes Methylated in Breast Cancer Cell Lines Are Not
Derepressed by Demethylation.As our results suggested that genes
prone to methylation might already be repressed by lineage-
speciﬁc factors, we investigated the extent to which DNA meth-
ylation might be important for their repression using the deme-
thylating agent 5-aza-2′-deoxycytidine (5-aza-dC). Treatment of
three breast cancer cell lines with 5-aza-dC led to the deme-
thylation and reexpression of DAZL, a gene whose expression is
known to be directly controlled by DNA methylation in normal
development (Fig. S4 C and D; ref. 22). The cancer testis antigen
GAGE4 was also derepressed as expected (23). We proﬁled gene
expression levels after 5-aza-dC or mock treatment using micro-
arrays, combining this with our methylation data to ascertain, in
an unbiased manner, the proportion of methylated genes that
were reactivated. Less than 10% of the silenced methylated
genes were derepressed by 5-aza-dC in the three breast cancer
lines, and derepression did not show a greater speciﬁcity for VM
genes (Fig. 4 C and D). A similar proportion of genes with
unmethylated promoters were derepressed by 5-aza-dC exposure
(Fig. 4C). Our arrays indicated that methylated CDH1 gene was
not reexpressed by 5-aza-dC in HBL100 cells; this result was
veriﬁed using quantitative RT-PCR (Fig. S4D).
As would be expected, 5-aza-dC treatments lead to signiﬁcant
but incomplete demethylation (Fig. S4C). To be sure that we
were not missing transcription effects because of inadequate de-
methylation, we took advantage of the DNA methyltransferase-
deﬁcient HCT116 DKO cells where DNA methylation is reduced
to 3–4% of that seen in wild-type (24, 25). We compared genes
reactivated in DKO cells with those reactivated by treating wild-
type HCT116 cells with 1 μM 5-aza-dC for 3 d, a dose shown to
reduce global methylation to 35% of control (26). As expected,
there was a signiﬁcant overlap in the methylated genes dere-
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Fig. 3. SRAM gene expression segregates breast cancer cell lines into cells of epithelial and mesenchymal lineage. (A–C) Dendrograms derived from un-
supervised hierarchical clustering of the cell lines based on expression of the 1,000 most variably expressed genes (A), percentage methylation of the 1,023 VM
genes (B), and expression values from a subset of genes that are SRAM (120 genes; C). The robustness of each sample’s cluster membership is shown below the
dendrogram, expressed as the percentage of permutations in which that sample grouped in its cluster (consensus clustering, see supplementary methods).
White, luminal A; gray, basal A; black, basal B (according to ref. 11). (D) The expression of EPCAM correlates with the two main clusters derived in C (P < 2.2 ×
10−16, Wilcoxon test). The cell lines are ordered based upon their expression of EPCAM. Color coding as for A–C. (E) Markers of epithelial and mesenchymal
lineages (SI Materials and Methods) are differentially expressed between the cell lines. The cell lines are ordered and color-coded as in D. Genes that were
silent in all 19 cell lines were excluded from the analysis.
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pressed by these two methods (Fig. S4E). However, despite the
fact that more methylated genes were derepressed in the DKO
cells than by 5-aza-dC treatment, this result still only represented
16.5% of methylated genes (Fig. S4F). These data suggest that
DNA methylation at promoters is not the primary mechanism
responsible for the repression of most methylated genes in cancer.
Lineage-Speciﬁc Aberrant Methylation Occurs in Primary Tumors. To
examine whether lineage-speciﬁc methylation also occurred in
primary tumors, we generated methylation proﬁles from 47 pri-
mary breast tumors. Firstly, we analyzed SRAM gene methylation
in the samples. After excluding probes that were methylated in
normal breast, SRAMprobes that weremethylated inEPCAM+ve
cell lines were signiﬁcantly more frequently methylated in primary
tumors than those speciﬁc for EPCAM−ve cell lines (Fig. 5 A and
B and Fig. S5A). A further analysis using all genes that showed
a signiﬁcant preference for methylation in EPCAM+ve or −ve cell
lines produced a similar result (Fig. S5B). Furthermore, genes that
were speciﬁcally repressed in normal luminal epithelial cells
(compared with stroma) were also signiﬁcantly more frequently
methylated in primary tumors than those genes that were active
(Fig. S5C). Within this list of genes we also found signiﬁcant
enrichments in genes previously reported to be frequently meth-
ylated in breast tumors (Table S1).
We then looked speciﬁcally at the methylation of important tu-
mor suppressor genes in breast cancer (BRCA1 andCDH1), as well
as other genes that have been frequently reported to bemethylated
and that might also be important in breast cancer biology (APC,
GSTP1, andESR1).GSTP1 andAPC are both SRAM genes meth-
ylated predominantly in EPCAM+ve cell lines (Fig. 4A) and were
frequently methylated in primary tumors (Fig. S5D). Both are
expressed in luminal progenitor cells but are down-regulated in
differentiated luminal cells, suggesting that theirmethylation could
be linked to terminal differentiation. BRCA1 displayed a similar
expressionpatternandwasmethylated toa level of>30% in4of the
47 (8.5%) primary tumors, a frequency consistent with previous
reports (27). In contrast, CDH1 and ESR1, which are both
expressed in epithelial cells, were infrequently methylated (2/47
and 0/47, respectively; Fig. S5D). The level ofCDH1methylation in
the two tumors was also comparatively low (31% and 34%). This
result is consistent with methylation rarely affecting genes that are
ordinarily expressed in that lineage. In cell lines, CDH1 methyla-
tion was speciﬁc to those with low EPCAM expression (Fig. S5D).
Our results demonstrate that primary tumors have epithelial-
speciﬁc methylation patterns. However, recent reports have sug-
gested that certain rare tumor types, claudin-low and metaplastic
tumors, might have mesenchymal characteristics (28). We tested
whether an expression signature composed of SRAM genes could
distinguish these tumors in that dataset. As predicted, most tumor
subtypes had a high EPCAM+ve score, but claudin-low and meta-
plastic tumors more closely resembled the SRAM expression
proﬁle of EPCAM−ve cell lines (Fig. 5C and Fig. S5E). Our sig-
nature was also predictive of EPCAM expression in tumors, as had
been the case for the cell lines (Fig. 5D). The expression levels of
a larger panel of marker genes further supported a mesenchymal
origin for claudin-low tumors and metaplastic tumors, although
the latter also expressed some epithelial markers (Fig. S5F).
Discussion
The methylation of CpG island promoters is a normal de-
velopmental process that is essential for repression of some
genes, such as those on the inactive X chromosome, imprinted
genes, and some tissue-speciﬁc genes (29). In cancer, many ad-
ditional promoters are both repressed and methylated. It is often
argued that methylation could also be instrumental in their re-
pression. However, our data suggest a model whereby in breast
cancer aberrant methylation occurs at genes that are already
repressed through normal lineage commitment and methylation
is generally not required for their repression (Fig. 5E). Lineage-
speciﬁc aberrant methylation has not been previously reported
but can be found in datasets of breast cancer methylation pat-
terns from a number of other studies (Table S1).
The ﬁnding that most cancer-associated aberrant methylation
occurs in genes that are already down-regulated has been alluded
to previously (30), and this phenomenon also occurs in normal
cultured neural cells (31). However, the literature contains many
examples of methylated genes being derepressed by 5-aza-dC in
cell lines, which has been central to the argument that aberrant
methylation causes tumor progression by silencing genes. In-
deed, one study assumed that in HCT116 cells, all methylated
genes are repressed because of methylation and used the amount
of deregulation induced by 5-aza-dC to estimate the size of the
methylome (5% of all genes; ref. 32). However, by using an
unbiased approach and directly measuring the proportions of
methylated and unmethylated genes that are actually dere-
pressed by 5-aza-dC, our results challenge this view. We ﬁnd that
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Fig. 4. In cell lines SRAM genes are repressed and methyl-
ated in a lineage-dependent manner, and most are not
controlled by DNA methylation. (A) Heat maps showing the
expression and methylation levels of SRAM genes in breast
cancer cell lines (color coded as in Fig. 3) together with their
EPCAM status. The cell lines and genes are clustered using
hierarchical clustering. See Fig. S4A for larger heat maps. (B)
Expression levels of differentially methylated SRAM genes in
different cell types in the normal breast. Lum, luminal epi-
thelial cells; Lum Pro, luminal epithelial progenitors (both
EPCAM+ve); Bas, basal myoepithelial cells; Stroma, mesen-
chymal stromal cells (both EPCAM−ve). Expression values are
median z scores, and differences between groups were
tested using Wilcoxon tests. (C) The percentages of meth-
ylated and unmethylated genes that were reactivated by 5-
aza-dC treatment in three breast cancer cell lines (Fisher’s
exact tests). (D) The percentage of CM and VM genes reac-
tivated by 5-aza-dC compared with the percentage of all
genes reactivated by 5-aza-dC. No signiﬁcant differences
were detected (χ2 tests). *P < 0.05; **P < 0.01; ***P < 0.001.
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5-aza-dC derepresses <10% of all methylated genes and that
25.5% of all genes are methylated in HCT116 cells. Repressive
histone marks may remain after treatment with 5-aza-dC (33),
indicating that DNA methylation may be one of many epigenetic
mechanisms involved in repression.
We found CDH1 and ESR1 to be rarely methylated in primary
tumors, and as these genes are expressed in epithelial cells, this
ﬁnding would be predicted by our model. Some studies using the
nonquantitative methylation-speciﬁc PCR (MSP) technique have
reported higher methylation frequencies of CDH1 and ESR1
(16, 34), including 72% in the case of CDH1 (35). However, MSP
may be prone to detecting low-level methylation at some genes. A
study using a quantitative version ofMSP agrees with our ﬁnding of
infrequentmethylationatCDH1 andESR1 (36).We foundgenuine
BRCA1 methylation in 8.5% of tumors, consistent with a previous
report (27). BRCA1 is down-regulated during terminal epithelial
differentiation, which couldmake it susceptible tomethylation.We
also note that disproportionately frequent BRCA1 methylation is
observed in metaplastic carcinomas (63% of a series of 27 tumors;
ref. 27). As these tumors appear to be mesenchymal and BRCA1 is
repressed in normal mesenchymal cells, this ﬁnding is consistent
with our model that methylation affects lineage-repressed genes.
The detection ofCDH1methylation by sensitive nonquantitative
techniques (MSP) could be due to the presence of stromal cells,
contaminating blood cells (37), or tumor cells that have undergone
epithelial-to-mesenchymal transition (EMT). The existence of
EMT is breast cancer is contentious, but it would be predicted to
down-regulateCDH1 and induce metastasis. EMTmight also lead
to CDH1 methylation under our model. However, as we did not
detect signiﬁcant CDH1 methylation, our data do not support ex-
tensive EMT in most breast tumors. A previous study also found
no differences in CDH1 expression between primary tumors and
their metastases (38). Whether EMT is responsible for the mixed
epithelial and mesenchymal characteristics in rare metaplastic
tumors (Fig. S5E) remains to be determined.
Although we observed that aberrantly methylated genes were
signiﬁcantly enriched for those that are bivalently marked in ES
cells (10), most of the affected genes lacked these marks. It is
possible, therefore, that in cancer, bivalent genes are prone to
methylation because they are lineage-speciﬁc and repressed,
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rather than because of a direct interaction of the polycomb and
DNA methylation machineries.
In summary, our data indicate that aberrant methylation is a
marker of lineage restriction in cancer. Although we cannot claim
that this ﬁnding applies to every aberrantly methylated gene, our
unbiased approach clearly demonstrates that normal developmental
repression inﬂuences whether genes become aberrantly methylated
in cancer. Our ﬁndings force a reappraisal of the likely efﬁcacy of
DNA demethylating agents in cancer therapy.
Materials and Methods
A brief summary of methods used is given below. For full details, see SI
Materials and Methods and Tables S2–S4.
Breast Cancer Cell Lines and Samples. Breast cancer cell lines were obtained
fromCancer ResearchUKorATCC.Wild-type andDKO (Dnmt1−/−, Dnmt3b−/−)
HCT116 cells were kind gifts from B. Vogelstein (24). HMECs were a gift from
E. Katz at the Edinburgh Breakthrough Breast Cancer Research Unit. SHEF-6
hES cell DNA was a gift from D. Hay (MRC Centre for Regenerative Medicine).
DNA from normal breast, fetal and adult brain, testis, liver, placenta, spleen,
blood, and colon were from Biochain, After approval by our ethical board, 47
fresh frozen unselected tumor samples were obtained through the Experi-
mental Cancer Medicine Centre in Edinburgh.
5-aza-dC Treatment. Cell lines were exposed to 1 μM5-aza-dC, refreshed every
24 h, for a total of 72 h.
Microarrays. We used Illumina Inﬁnium Human Methylation27 beadarrays
and Illumina human HT12 Expression beadarrays. All data have been sub-
mitted to the Gene Expression Omnibus (GEO) database (accession no.
GSE26990).
Bioinformatic Analyses. Bioinformatic analyses were performed using R
(version 2.9.2). Ensembl 54 (NCBI36) gene annotations were used throughout.
In cell lines unmethylated genes were deﬁned as those with ≤30% meth-
ylation and methylated ones as ≥70%. In tumor samples methylated genes
were deﬁned as those with >30% methylation due to the heterogeneity of
the samples. We deﬁned groups of genes with different methylation pat-
terns as follows: CU, unmethylated in all cell lines; CM, methylated in all cell
lines or all but one cell line; VM, methylated in at least four and unmethy-
lated in at least four cell lines. Only CpGs within 200 bp of transcription start
sites were considered in our analyses. SRAM genes were VM genes that had
signiﬁcantly lower expression when methylated (one-sided Wilcoxon test).
The speciﬁcity of a gene expression pattern was measured using a method
based on information theory (SI Materials and Methods). Datasets were
downloaded from data repositories or individual papers as appropriate.
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